Cargando…

Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys

The latent viral reservoir is the critical barrier for the development of an HIV-1 cure. Previous studies have shown that potent HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) administered at the time of antiretroviral therapy (ART) discontinuation can exert direct antiviral effects, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borducchi, Erica N., Liu, Jinyan, Nkolola, Joseph P., Cadena, Anthony M., Yu, Wen-Han, Fischinger, Stephanie, Broge, Thomas, Abbink, Peter, Mercado, Noe B., Chandrashekar, Abishek, Jetton, David, Peter, Lauren, McMahan, Katherine, Moseley, Edward T., Bekerman, Elena, Hesselgesser, Joseph, Li, Wenjun, Lewis, Mark G., Alter, Galit, Geleziunas, Romas, Barouch, Dan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237629/ https://www.ncbi.nlm.nih.gov/pubmed/30283138 http://dx.doi.org/10.1038/s41586-018-0600-6

Ejemplares similares

Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation
por: Liu, Po-Ting, et al.
Publicado: (2020)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys
por: Moldt, Brian, et al.
Publicado: (2022)

Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques
por: Cadena, Anthony M., et al.
Publicado: (2021)

Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques
por: Walker-Sperling, Victoria E. K., et al.
Publicado: (2022)

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
por: Vidal, Samuel J., et al.
Publicado: (2021)

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2016)

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
por: Hsu, Denise C., et al.
Publicado: (2021)

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
por: Ventura, John D., et al.
Publicado: (2022)

PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy
por: Bekerman, Elena, et al.
Publicado: (2019)

Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys
por: Keele, Brandon F., et al.
Publicado: (2017)

Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection
por: Bekerman, Elena, et al.
Publicado: (2020)

Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys
por: Barouch, Dan H., et al.
Publicado: (2013)

CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques
por: Fan, Jin, et al.
Publicado: (2019)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia
por: Nishimura, Yoshiaki, et al.
Publicado: (2020)

Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant
por: Liu, Jinyan, et al.
Publicado: (2022)

A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation()
por: Fischinger, Stephanie, et al.
Publicado: (2019)

A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques
por: Nkolola, Joseph P., et al.
Publicado: (2022)

Search for small molecule activators of latent HIV
por: Geleziunas, Romas, et al.
Publicado: (2012)

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
por: Obregon-Perko, Veronica, et al.
Publicado: (2021)

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
por: Liu, Jinyan, et al.
Publicado: (2022)

Prevention of SHIV transmission by topical IFN-β treatment
por: Veazey, Ronald S., et al.
Publicado: (2016)

Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation
por: Cardozo-Ojeda, E Fabian, et al.
Publicado: (2021)

Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
por: Collier, Ai-ris Y, et al.
Publicado: (2021)

Assessing the impact of autologous neutralizing antibodies on viral rebound in postnatally SHIV-infected ART-treated infant rhesus macaques
por: Mainou, Ellie, et al.
Publicado: (2023)

Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions
por: Bartsch, Yannic C., et al.
Publicado: (2023)

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice
por: Larocca, Rafael A., et al.
Publicado: (2021)

Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012)

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
por: Pauthner, Matthias G., et al.
Publicado: (2019)

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
por: Bekerman, Elena, et al.
Publicado: (2023)

The Antibodiome—Mapping the Humoral Immune Response to HIV
por: Butler, Audrey L., et al.
Publicado: (2019)

Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys
por: Whitney, James B., et al.
Publicado: (2014)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies
por: Dugast, Anne-Sophie, et al.
Publicado: (2014)

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
por: Collier, Ai-ris Y., et al.
Publicado: (2021)

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques
por: He, Xuan, et al.
Publicado: (2022)

Human Immunodeficiency Virus Type 1-Associated Cd4 Downmodulation
por: Geleziunas, Romas, et al.
Publicado: (1994)

Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
por: Bartsch, Yannic C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ietf5qias1a5j1jtmmm8uo9bjp